On PHIâ€™s website, founder and CEO Peter Egelberg comments on his presentation at SPIE 2018 in San Francisco â€œThe evolution of Phase Holographic Imaging from a research idea to publicly traded companyâ€�, see www.phiab.se/commentary/commentary-180204.
Phase Holographic Imaging (PHI) leads the ground-breaking development of time-lapse cytometry instrumentation and software. With the first instrument introduced in 2011, the company today offers a range of products for long-term quantitative analysis of living cell dynamics that circumvent the drawbacks of traditional methods requiring toxic stains. Headquartered in Lund, Sweden, PHI trades through a network of international distributors. Committed to promoting the science and practice of time-lapse cytometry, PHI is actively expanding its customer base and scientific collaborations in cancer research, inflammatory and autoimmune diseases, stem cell biology, gene therapy, regenerative medicine and toxicological studies.
Latest posts by Sarah Thompson (see all)
- Solar-Log's Anthony Conklin Speaking at Solar Asset Management North America - February 23, 2018
- Ubisec System Recognized as Top 500 for Managed IT Services - February 23, 2018
- Bay City Connections Emphasizes Growth-Focused Travel - February 23, 2018